ATE411342T1 - Scfv antikörper gegen krankheiten-assoziierte moleküle - Google Patents

Scfv antikörper gegen krankheiten-assoziierte moleküle

Info

Publication number
ATE411342T1
ATE411342T1 AT00974682T AT00974682T ATE411342T1 AT E411342 T1 ATE411342 T1 AT E411342T1 AT 00974682 T AT00974682 T AT 00974682T AT 00974682 T AT00974682 T AT 00974682T AT E411342 T1 ATE411342 T1 AT E411342T1
Authority
AT
Austria
Prior art keywords
antibodies against
against disease
associated molecules
scfv antibodies
scfv
Prior art date
Application number
AT00974682T
Other languages
English (en)
Inventor
Alan Kingsman
Susan Mary Kingsman
Christopher Robert Bebbington
Miles William Carroll
Fiona Margaret Ellard
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE411342T1 publication Critical patent/ATE411342T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Conductive Materials (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00974682T 1999-11-18 2000-11-13 Scfv antikörper gegen krankheiten-assoziierte moleküle ATE411342T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies

Publications (1)

Publication Number Publication Date
ATE411342T1 true ATE411342T1 (de) 2008-10-15

Family

ID=38233183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974682T ATE411342T1 (de) 1999-11-18 2000-11-13 Scfv antikörper gegen krankheiten-assoziierte moleküle

Country Status (5)

Country Link
US (2) US20070161080A1 (de)
EP (1) EP2161286A1 (de)
KR (1) KR20020049054A (de)
AT (1) ATE411342T1 (de)
DE (1) DE60040555D1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
EP3445788B1 (de) * 2016-04-22 2022-01-19 Alligator Bioscience AB Neue bispezifische polypeptide gegen cd137
EP3655439A1 (de) 2017-07-20 2020-05-27 Aptevo Research and Development LLC An 5t4 und 4-1bb bindende antigenbindende proteine und zugehörige zusammensetzungen und verfahren
EP3704151A4 (de) 2017-11-01 2021-07-28 NantBio, Inc. Il8-blockierender emt-signalweg und überwindung von krebsstammzellen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
EP1036091B2 (de) * 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle

Also Published As

Publication number Publication date
US20110052577A1 (en) 2011-03-03
KR20020049054A (ko) 2002-06-24
EP2161286A1 (de) 2010-03-10
DE60040555D1 (de) 2008-11-27
US20070161080A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2001036486A3 (en) Scfv antibodies against disease associated molecules
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
FR19C1028I2 (fr) Anticorps greffes avec cdr humains et fragments de ces anticorps
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
PT1333887E (pt) Metodo de tratamento de desordens musculares
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
DE69931624D1 (de) Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen
JP2005524663A5 (de)
NO20034020L (no) Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
ATE411342T1 (de) Scfv antikörper gegen krankheiten-assoziierte moleküle
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
EP1742654A4 (de) Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
KR910007531A (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties